What is the optimal concentration of anti-RIgG(HL)Fab-C-MMAF ADC for in vitro cell viability assays?

The optimal concentration of the anti-RIgG(HL)Fab-C-MMAF ADC for in vitro cell viability assays can vary depending on the specific cell line and experimental setup. It is recommended to start with a range of concentrations, typically between 1 nM to 100 nM, to determine the most effective dose for inducing cytotoxicity in your target cells.

What controls are necessary when using anti-RIgG(HL)Fab-C-MMAF ADC in experiments?

When using the anti-RIgG(HL)Fab-C-MMAF ADC in experiments, it is important to include both positive and negative controls. A non-targeting ADC can serve as a negative control, while a known target-specific ADC can act as a positive control. Additionally, including untreated cells as a baseline control is essential for accurate data interpretation.

Is it possible to combine anti-RIgG(HL)Fab-C-MMAF ADC with other therapeutic agents in experiments?

Yes, the anti-RIgG(HL)Fab-C-MMAF ADC can be combined with other therapeutic agents, such as chemotherapy drugs or immune checkpoint inhibitors, in combination studies. However, careful optimization is required to determine the appropriate dosing and timing to achieve synergistic effects while minimizing off-target toxicity.

What is the recommended incubation time for anti-RIgG(HL)Fab-C-MMAF ADC in cell-based assays?

The recommended incubation time for the anti-RIgG(HL)Fab-C-MMAF ADC in cell-based assays can vary, but typically ranges from 24 to 72 hours, depending on the cell type and the desired endpoint. Longer incubation periods may be necessary to observe full cytotoxic effects, particularly in slow-growing cell lines.

What is the expected outcome when using anti-RIgG(HL)Fab-C-MMAF ADC in a target validation study?

When using the anti-RIgG(HL)Fab-C-MMAF ADC in a target validation study, the expected outcome is the selective killing of cells expressing the target antigen. This ADC is designed to deliver MMAF specifically to target cells, leading to microtubule disruption and cell death, thereby confirming the target's role in cell survival or proliferation.

What troubleshooting steps can be taken if the anti-RIgG(HL)Fab-C-MMAF ADC does not show expected cytotoxicity?

If the anti-RIgG(HL)Fab-C-MMAF ADC does not show expected cytotoxicity, several troubleshooting steps can be taken: (1) Verify the expression of the target antigen on the cells; (2) Check the integrity and concentration of the ADC; (3) Optimize the incubation time and ADC concentration; (4) Ensure that the linker cleavage is occurring as expected within the cells. Adjusting these parameters may help achieve the desired cytotoxic effect.

Home
Products
Anti-Ab ADCs
IgG (H+L)
anti-RIgG(HL)Fab-C-MMAF ADC

anti-RIgG(HL)Fab-C-MMAF ADC (CAT#: ADC-AA-038)

This ADC product is comprised of a Fab fragment of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAF. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG(H+L)

Overview
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system, which is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. IgG is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses.

Overview
Fab fragment of anti-rabbit IgG(H+L) specific polyclonal IgG antibody

Species Reactivity
Rabbit

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-038. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

We found the anti-RIgG(HL)Fab-C-MMAF ADC from Creative Biolabs to be exceptionally effective. Its ability to induce cell death without added toxicity has streamlined our antibody candidate screenings.

Excellent

This ADC product exceeded our expectations in terms of safety and efficiency. The cleavable linker to MMAF works flawlessly, providing consistent results in our experiments.

Excellent

The anti-RIgG(HL)Fab-C-MMAF ADC is a reliable and efficient tool for our lab's needs. Its low toxicity profile has allowed us to conduct more experiments with greater confidence.

Excellent

We've been impressed with the performance of Creative Biolabs' anti-RIgG(HL)Fab-C-MMAF ADC. It's an excellent alternative for ADC candidate screening, offering both safety and efficacy.

Excellent

Using the anti-RIgG(HL)Fab-C-MMAF ADC has simplified our screening processes. The product's cytotoxicity and lack of toxicity without a primary antibody make it a valuable addition to our lab.

Excellent

This product has proven to be a cost-effective solution for our ADC candidate evaluations. The anti-RIgG(HL)Fab-C-MMAF ADC from Creative Biolabs offers the perfect balance of safety and efficiency.

Q: 1: What is the optimal concentration of anti-RIgG(HL)Fab-C-MMAF ADC for in vitro cell viability assays?
A: The optimal concentration of the anti-RIgG(HL)Fab-C-MMAF ADC for in vitro cell viability assays can vary depending on the specific cell line and experimental setup. It is recommended to start with a range of concentrations, typically between 1 nM to 100 nM, to determine the most effective dose for inducing cytotoxicity in your target cells.
Q: 2: What controls are necessary when using anti-RIgG(HL)Fab-C-MMAF ADC in experiments?
A: When using the anti-RIgG(HL)Fab-C-MMAF ADC in experiments, it is important to include both positive and negative controls. A non-targeting ADC can serve as a negative control, while a known target-specific ADC can act as a positive control. Additionally, including untreated cells as a baseline control is essential for accurate data interpretation.
Q: 3: Is it possible to combine anti-RIgG(HL)Fab-C-MMAF ADC with other therapeutic agents in experiments?
A: Yes, the anti-RIgG(HL)Fab-C-MMAF ADC can be combined with other therapeutic agents, such as chemotherapy drugs or immune checkpoint inhibitors, in combination studies. However, careful optimization is required to determine the appropriate dosing and timing to achieve synergistic effects while minimizing off-target toxicity.
Q: 4: What is the recommended incubation time for anti-RIgG(HL)Fab-C-MMAF ADC in cell-based assays?
A: The recommended incubation time for the anti-RIgG(HL)Fab-C-MMAF ADC in cell-based assays can vary, but typically ranges from 24 to 72 hours, depending on the cell type and the desired endpoint. Longer incubation periods may be necessary to observe full cytotoxic effects, particularly in slow-growing cell lines.
Q: 5: What is the expected outcome when using anti-RIgG(HL)Fab-C-MMAF ADC in a target validation study?
A: When using the anti-RIgG(HL)Fab-C-MMAF ADC in a target validation study, the expected outcome is the selective killing of cells expressing the target antigen. This ADC is designed to deliver MMAF specifically to target cells, leading to microtubule disruption and cell death, thereby confirming the target's role in cell survival or proliferation.
Q: 6: What troubleshooting steps can be taken if the anti-RIgG(HL)Fab-C-MMAF ADC does not show expected cytotoxicity?
A: If the anti-RIgG(HL)Fab-C-MMAF ADC does not show expected cytotoxicity, several troubleshooting steps can be taken: (1) Verify the expression of the target antigen on the cells; (2) Check the integrity and concentration of the ADC; (3) Optimize the incubation time and ADC concentration; (4) Ensure that the linker cleavage is occurring as expected within the cells. Adjusting these parameters may help achieve the desired cytotoxic effect.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-035	anti-RIgG(HL)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-047	anti-Rat IgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
WJY-0423-LS108	Protein G-Amanitin ADC	Cleavable linkers	Amanitin
ADC-AA-062	Anti-HIgG(Fc)Fab-C-DX8951 ADC	Cleavable linkers	DX8953
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-W-604	Anti-FUT3-Mc-VC-PABC-MMAF ADC-3	MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.